Cargando…

Validation of pharmacodynamic assays to evaluate the clinical efficacy of an antisense compound (AEG 35156) targeted to the X-linked inhibitor of apoptosis protein XIAP

The inhibitor of apoptosis protein, XIAP, is frequently overexpressed in chemoresistant human tumours. An antisense oligonucleotide (AEG 35156/GEM 640) that targets XIAP has recently entered phase I trials in the UK. Method validation data are presented on three pharmacodynamic assays that will be u...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cummings, J, Ward, T H, LaCasse, E, Lefebvre, C, St-Jean, M, Durkin, J, Ranson, M, Dive, C
Formato:	Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2005
Materias:	Translational Therapeutics
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2362094/ https://www.ncbi.nlm.nih.gov/pubmed/15685240 http://dx.doi.org/10.1038/sj.bjc.6602363

Ejemplares similares

Method validation and preliminary qualification of pharmacodynamic biomarkers employed to evaluate the clinical efficacy of an antisense compound (AEG35156) targeted to the X-linked inhibitor of apoptosis protein XIAP
por: Cummings, J, et al.
Publicado: (2006)

A small molecule inhibitor of XIAP induces apoptosis and synergises with vinorelbine and cisplatin in NSCLC
por: Dean, E J, et al.
Publicado: (2010)

Elevated XIAP expression alone does not confer chemoresistance
por: Seeger, J M, et al.
Publicado: (2010)

Survivin and XIAP: two valuable biomarkers in medullary thyroid carcinoma
por: Werner, Thomas A, et al.
Publicado: (2016)

The hollow fibre assay as a model for in vivo pharmacodynamics of fluoropyrimidines in colon cancer cells
por: Temmink, O H, et al.
Publicado: (2007)

MLH1 expression sensitises ovarian cancer cells to cell death mediated by XIAP inhibition
por: Ding, X, et al.
Publicado: (2009)

Double inhibition of XIAP and Bcl-2 axis is beneficial for retrieving sensitivity of renal cell cancer to apoptosis
por: Bilim, V, et al.
Publicado: (2008)

Evaluation of cell death mechanisms induced by the vascular disrupting agent OXi4503 during a phase I clinical trial
por: Cummings, J, et al.
Publicado: (2012)

Safety, tolerability, pharmacokinetics and pharmacodynamics of AZD8055 in advanced solid tumours and lymphoma
por: Naing, A, et al.
Publicado: (2012)

Phase I and pharmacodynamic study of high-dose NGR–hTNF in patients with refractory solid tumours
por: Zucali, P A, et al.
Publicado: (2013)

Phase I pharmacokinetic and pharmacodynamic study of the prenyl transferase inhibitor AZD3409 in patients with advanced cancer
por: Appels, N M G M, et al.
Publicado: (2008)

Preclinical efficacy of the bioreductive alkylating agent RH1 against paediatric tumours
por: Hussein, D, et al.
Publicado: (2009)

Directing HER4 mRNA expression towards the CYT2 isoform by antisense oligonucleotide decreases growth of breast cancer cells in vitro and in vivo
por: Nielsen, T O, et al.
Publicado: (2013)

Assessing proliferation, cell-cycle arrest and apoptotic end points in human buccal punch biopsies for use as pharmacodynamic biomarkers in drug development
por: Camidge, D R, et al.
Publicado: (2005)

Contribution of HIF-1 and drug penetrance to oxaliplatin resistance in hypoxic colorectal cancer cells
por: Roberts, D L, et al.
Publicado: (2009)

Apoptosis assays with lymphoma cell lines: problems and pitfalls
por: Mattes, M J
Publicado: (2007)

Tyrphostins reduce chemotherapy-induced intestinal injury in mice: assessment by a biochemical assay
por: Zlotnik, Y, et al.
Publicado: (2005)

Tumour biomechanical response to the vascular disrupting agent ZD6126 in vivo assessed by magnetic resonance elastography
por: Li, J, et al.
Publicado: (2014)

Anti-tumour activity of two novel compounds in cisplatin-resistant testicular germ cell cancer
por: Nitzsche, B, et al.
Publicado: (2012)

In vivo and in vitro properties of STX2484: a novel non-steroidal anti-cancer compound active in taxane-resistant breast cancer
por: Stengel, C, et al.
Publicado: (2014)

35156 Sensory mechanisms of atypical motor variability and regularity in autism spectrum disorder
por: Shafer, Robin L., et al.
Publicado: (2021)

The effects of CCR5 inhibition on regulatory T-cell recruitment to colorectal cancer
por: Ward, S T, et al.
Publicado: (2015)

Novel pyrrolo-1,5-benzoxazepine compounds display significant activity against resistant chronic myeloid leukaemia cells in vitro, in ex vivo patient samples and in vivo
por: Bright, S A, et al.
Publicado: (2010)

Transport kinetics of four- and six-coordinate platinum compounds in the multicell layer tumour model
por: Modok, S, et al.
Publicado: (2007)

Pharmacologically directed strategies in academic anticancer drug discovery based on the European NCI compounds initiative
por: Hendriks, Hans R, et al.
Publicado: (2017)

Enhancing the immunogenicity of tumour lysate-loaded dendritic cell vaccines by conjugation to virus-like particles
por: Win, S J, et al.
Publicado: (2012)

Effects of oestrogens and anti-oestrogens on normal breast tissue from women bearing BRCA1 and BRCA2 mutations
por: Bramley, M, et al.
Publicado: (2006)

Population pharmacodynamic modelling of midazolam induced sedation in terminally ill adult patients
por: Franken, Linda G., et al.
Publicado: (2017)

Antitumour activity of the novel flavonoid Oncamex in preclinical breast cancer models
por: Martínez-Pérez, Carlos, et al.
Publicado: (2016)

Combined modalities of resistance in an oxaliplatin-resistant human gastric cancer cell line with enhanced sensitivity to 5-fluorouracil
por: Chen, C-C, et al.
Publicado: (2007)

H-Ras oncogene counteracts the growth-inhibitory effect of genistein in T24 bladder carcinoma cells
por: Li, C, et al.
Publicado: (2005)

NGR-TNF, a novel vascular-targeting agent, does not induce cytokine recruitment of proangiogenic bone marrow-derived cells
por: Di Matteo, P, et al.
Publicado: (2013)

In vitro and in vivo reversal of resistance to 5-fluorouracil in colorectal cancer cells with a novel stealth double-liposomal formulation
por: Fanciullino, R, et al.
Publicado: (2007)

Numerical and functional defects of blood dendritic cells in early- and late-stage breast cancer
por: Pinzon-Charry, A, et al.
Publicado: (2007)

Macrophage migration inhibitory factor produced by the tumour stroma but not by tumour cells regulates angiogenesis in the B16-F10 melanoma model
por: Girard, E, et al.
Publicado: (2012)

Expression of V(1A) and GRP receptors leads to cellular transformation and increased sensitivity to substance-P analogue-induced growth inhibition
por: MacKinnon, A C, et al.
Publicado: (2005)

Activating oxidative phosphorylation by a pyruvate dehydrogenase kinase inhibitor overcomes sorafenib resistance of hepatocellular carcinoma
por: Shen, Y-C, et al.
Publicado: (2013)

Stat3 activation in human endometrial and cervical cancers
por: Chen, C-L, et al.
Publicado: (2007)

Paclitaxel resistance in untransformed human mammary epithelial cells is associated with an aneuploidy-prone phenotype
por: Bouchet, B P, et al.
Publicado: (2007)

A mathematical modelling tool for predicting survival of individual patients following resection of glioblastoma: a proof of principle
por: Swanson, K R, et al.
Publicado: (2008)

Cannot write session to /tmp/vufind_sessions/sess_qfrcuo380crn1gbmn49i1k1ffn